AD/PD 2021 | Is there an association between AD and COVID-19?

Katja Kanninen, PhD, MSc, University of East Finland, Kuopio, Finland, describes a panel discussion on the impact of COVID-19 on neurodegenerative diseases as one of her key highlights from the AD/PD 2021 conference. A number of questions remain regarding whether there is an increased risk of COVID-19 in patients with Alzheimer’s disease (AD), as well as whether there is an increased risk of developing AD due to COVID-19. She suggests that further study of common risk factors such as age, inflammatory processes and apolipoprotein E (APOE) should be completed in order to elucidate any potential associations between COVID-19 and AD. This interview took place during the AD/PD™ 2021 conference.